There were 2,247 press releases posted in the last 24 hours and 439,987 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image